![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Codexis Inc | NASDAQ:CDXS | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.25 | 7.58% | 3.55 | 3.42 | 3.70 | 3.6599 | 3.31 | 3.31 | 645,856 | 01:00:00 |
“It is an honor to be named as a finalist for the 2023 Bloom Burton Award. Leading the team at Sierra Oncology to bring momelotinib to the patients who would most benefit was an energizing experience and a highlight of my career. GSK recognized the value of the compound the same way we did and joined forces with us to help accelerate delivery to patients on a global scale,” said Dr. Dilly. “I am incredibly grateful to the physicians and patients who participated in our clinical trials, and the entire team at Sierra who worked diligently to meet demanding timelines throughout the development process. This nomination is a recognition of the work of the entire team and our collective vision to transform promise into patient impact.”
The Bloom Burton Award finalists and winner are chosen by an independent panel of judges consisting of international leaders in healthcare investment, entrepreneurship and journalism. The winner will be announced live at the Bloom Burton Award Gala on September 28, 2023, at the Four Seasons Hotel Toronto. For more information, please visit www.bloomburton.com/gala.
About Codexis
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the Company is currently developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. For more information, visit https://www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5ae806bb-f003-408b-8f68-d17276433729
1 Year Codexis Chart |
1 Month Codexis Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions